Replies to post #108409 on Biotech Values

[DFRAI]

Microcapfun - just for you, more pumping re ONCY out of Cancer Journal
Those pesky doctors seem to think that reovirus may have some utility.

Cancer Journal - Reo and Pediatric Sarcomas 9-Nov-10 07:59 am
They have completed pre-clinical research on pediatric sarcomas and Reolysin. "These results suggest that Reolysin alone or in combination with other cytotoxic agents may be effective therapy in pediatric sarcomas".

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenograftsPooja Hingorani MD1,*,†, Wendong Zhang BS2, Juan Lin PhD3, Laibin Liu BS4, Chandan Guha MD4, E. Anders Kolb MD5Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25741

Copyright © 2010 American Cancer Society
Issue
Cancer
Early View (Articles online in advance of print)
Additional Information(Show All)
How to CiteAuthor InformationPublication History
How to Cite
Hingorani, P., Zhang, W., Lin, J., Liu, L., Guha, C. and Kolb, E. A. , Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer, n/a. doi: 10.1002/cncr.25741

Author Information
1Department of Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona
2Department of Pediatric Hematology/Oncology, Albert Einstein College of Medicine, Bronx, New York
3Department of Biostatistics, Albert Einstein College of Medicine, Bronx, New York
4Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, New York
5Nemours Center for Childhood Cancer Research, Alfred I. duPont Hospital for Children, Wilmington, Delaware
Email: Pooja Hingorani MD ([e-mail])

*Correspondence: Pooja Hingorani MD, Phoenix Children's Hospital, 1919 E Thomas Road, Phoenix, AZ 85016

†Fax: [phone]

Publication History
Article first published online: 8 NOV 2010
Manuscript Accepted: 13 SEP 2010
Manuscript Revised: 9 SEP 2010
Manuscript Received: 16 JUN 2010
Abstract
BACKGROUND:
Despite advancement in therapies, overall survival rates for relapsed pediatric sarcomas are dismal. Newer therapies are needed to effectively salvage these patients. Newer therapies are needed to effectively salvage herapies, overall survival rates for these patients. Oncolytic viruses (such as reovirus) and other genetically altered viruses (such as herpes simplex viruses and adenoviruses) have shown efficacy in a variety of solid tumors including sarcomas. Reolysin is an unmodified oncolytic reovirus that selectively replicates in Ras-activated cancer cells while not causing any significant human illness in its wild form.METHODS:
By using a panel of pediatric sarcoma cell lines in vitro and flank xenografts in vivo, Reolysin was evaluated as a single agent and in combination with cisplatin and radiation therapy. Electron microscopy and immunohistochemistry was used to demonstrated a cytopathic effect in treated tumors.
RESULTS:
Reolysin inhibited the proliferation and viability of sarcoma cell lines at a dose of 1 to 10 virus particles per cell. In vivo, 5 × 109 plaque-forming units (PFU) administered via the tail vein every other day for 3 doses every 21 days inhibited the growth of tumor xenografts with improvement in event-free survival. In the SKES1 Ewing sarcoma line, there was therapeutic enhancement when reovirus was administered in combination with radiation or cisplatin. In the RH30 line and the OS33 line, therapeutic enhancement was demonstrated with radiation and cisplatin, respectively.
CONCLUSIONS:
These results suggest that Reolysin alone or in combination with other cytotoxic agents may be effective therapy in pediatric sarcomas. Cancer 2010. © 2010 American Cancer Society.